Trade Alert: Big News Pending for SIGA Technologies, Inc. Print E-mail
By M.E.Garza   
Tuesday, 24 November 2009 03:00

BioMedReports has learned that shares of this bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses is expecting big news and government orders.

Subscribers were alerted yesterday that a series of big government orders are anticipated to be announced "any day now," after sources confirmed to us that the official news and first purchase order could come within days.

SIGA Technologies, Inc. (NASDAQ:SIGA) has been trading up since late Thursday, when funds and others who were holding short positions started to cover in anticipation of this news.

The stock has a very, very low float and the price has been rising on just a little volume.  It is not unrealistic to think that the stock could soar and see $15 -$20 range on the news (based on our own technical analysis).

In May, SIGA announced that it had submitted its response to the Biomedical Advance Research and Development Authority (BARDA) regarding the agency's outstanding RFP for the procurement of 1.7 million courses of a smallpox antiviral.

The U.S. government considers the inhaled smallpox virus the single biggest biological threat which could be used against Americans via a terrorist attack.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

Please learn more about the company here:

Disclosure: No Positions

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus